Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Saturday. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald lifted their price target on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an overweight rating in a research note on Thursday, August 1st.

Vanda Pharmaceuticals Trading Down 0.4 %

VNDA opened at $5.08 on Friday. The firm has a market cap of $295.65 million, a P/E ratio of -63.50 and a beta of 0.77. Vanda Pharmaceuticals has a 12 month low of $3.30 and a 12 month high of $6.75. The stock has a 50-day moving average of $5.48 and a 200 day moving average of $5.11.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter. The firm had revenue of $50.47 million during the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. On average, research analysts forecast that Vanda Pharmaceuticals will post -0.49 earnings per share for the current fiscal year.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its stake in Vanda Pharmaceuticals by 18.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock worth $66,000 after buying an additional 2,425 shares in the last quarter. Panagora Asset Management Inc. grew its holdings in Vanda Pharmaceuticals by 4.3% in the second quarter. Panagora Asset Management Inc. now owns 60,434 shares of the biopharmaceutical company’s stock worth $341,000 after purchasing an additional 2,509 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Vanda Pharmaceuticals by 65.9% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 4,387 shares during the last quarter. Susquehanna Fundamental Investments LLC grew its holdings in Vanda Pharmaceuticals by 2.1% in the second quarter. Susquehanna Fundamental Investments LLC now owns 287,677 shares of the biopharmaceutical company’s stock worth $1,625,000 after purchasing an additional 5,994 shares during the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in Vanda Pharmaceuticals in the second quarter worth $39,000. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.